Cerevance
9 known investors
Cerevance is a clinical-stage drug discovery and development company developing non-dopaminergic, orally-delivered therapies for brain and central nervous system disorders, including Parkinson's disease, schizophrenia, Alzheimer's disease, and ALS. It uses a proprietary human brain tissue profiling platform (NETSseq) and advances candidates such as solengepras (CVN424), CVN293, and CVN766 through clinical trials.
Founders & leadership
CT
Craig ThompsonChief Executive Officer
SV
Sagar VaidyaChief Medical Officer
CA
Carrie Ann CookChief Business Officer
Investors · 9
Foresite Capital✓ verifiedLarkspur
GV (Google Ventures)✓ verifiedMountain View · $250K – $50M
Dementia Discovery Fund✓ verifiedLondon
SV Life Sciences✓ verifiedBoston
Dementia DiscoveryLondon
Lightstone VenturesPortola Valley
SV Health InvestorsBoston · $1M – $20M
Agent CapitalreportedWaltham
Dolby Family VenturesreportedSan Francisco